Asthma: where beyond steroids?
The prevalence of asthma is increasing dramatically despite major changes in monitoring and treatment of this disease. Currently available bronchodilators and anti-inflammatory drugs are effective in most patients, although these can have side effects and are mainly symptomatic. Many drugs are now in development for the treatment of asthma. Most of these new therapies are aimed at inhibition of the inflammatory components, with better safety profiles than steroids.
Bertrand
C P
CP
Institut de Recherche Jouveinal/Parke Davis, Fresnes, France. claude.bertrand@wl.com
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000378:metabolism; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D018925:Chemokines / Q000494:pharmacology; D053818:Chymases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007262:Infusions, Intravenous; D007378:Interleukins / Q000494:pharmacology; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D012697:Serine Endopeptidases / Q000378:metabolism; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D053802:Tryptases
D018925:Chemokines; D007378:Interleukins; D020024:Leukotriene Antagonists; D007073:Immunoglobulin E; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D012697:Serine Endopeptidases; C083294:chymase 2; D053818:Chymases; D053802:Tryptases